Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
暂无分享,去创建一个
Alan Forrest | Arnold Louie | G. Drusano | S. Bhavnani | P. Ambrose | T. Gumbo | A. Forrest | Paul G Ambrose | George L Drusano | Sujata M Bhavnani | A. Louie | Tawanda Gumbo | Christopher M Rubino | C. Rubino
[1] G. Drusano,et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.
[2] W. Craig. Pharmacodynamics of Antimicrobials: General Concepts and Applications , 2001 .
[3] H. Eagle,et al. THE EFFECTIVE CONCENTRATIONS OF PENICILLIN IN VITRO AND IN VIVO FOR STREPTOCOCCI, PNEUMOCOCCI, AND TREPONEMA PALLIDUM , 1950, Journal of bacteriology.
[4] W. Craig,et al. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin , 2002 .
[5] J. Loutit,et al. Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia , 2006, Antimicrobial Agents and Chemotherapy.
[6] M. Dudley,et al. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. , 2000, Current opinion in microbiology.
[7] H. Eagle,et al. Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. , 1950, The American journal of medicine.
[8] G. Drusano,et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. , 2004, The Journal of infectious diseases.
[9] Ronald N. Jones,et al. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. , 2000, The Journal of antimicrobial chemotherapy.
[10] R. Owens,et al. Clinical pharmacodynamics of quinolones. , 2003, Infectious disease clinics of North America.
[11] Jerome J. Schentag,et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. , 1997, The Journal of antimicrobial chemotherapy.
[12] Ronald N. Jones,et al. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] G. Drusano,et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. , 2005, Diagnostic microbiology and infectious disease.
[14] E. Ludwig,et al. Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections , 2004, Antimicrobial Agents and Chemotherapy.
[15] Thaddeus H. Grasela,et al. Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections , 2001, Antimicrobial Agents and Chemotherapy.
[16] B. Cirincione,et al. Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections , 2007, Antimicrobial Agents and Chemotherapy.
[17] G. Drusano,et al. Antimicrobial Pharmacodynamics in Theory and Clinical Practice , 2007 .
[18] Robert Leary,et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.
[19] G L Drusano,et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.
[20] W. Craig,et al. In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria , 2000, Antimicrobial Agents and Chemotherapy.
[21] I. Gould,et al. The post-antibiotic effect. , 1993, The Journal of antimicrobial chemotherapy.
[22] V. Lorian. Antibiotics in laboratory medicine , 2005 .
[23] J J Schentag,et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.
[24] W. Craig,et al. Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .
[25] Jerome J. Schentag,et al. Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme , 2003, Clinical pharmacokinetics.
[26] P. Iversen,et al. Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection , 2003, Antimicrobial Agents and Chemotherapy.
[27] G. Woodnutt. Pharmacodynamics to combat resistance. , 2000, The Journal of antimicrobial chemotherapy.
[28] W. Craig,et al. Killing and regrowth of bacteria in vitro: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[29] Ronald N. Jones,et al. Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi , 2005, Antimicrobial Agents and Chemotherapy.
[30] W. Craig,et al. In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid) , 2002, Antimicrobial Agents and Chemotherapy.
[31] H. Eagle,et al. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. , 1953, The New England journal of medicine.
[32] R. Echols. The selection of appropriate dosages for intravenous ciprofloxacin. , 1993, Journal of Antimicrobial Chemotherapy.
[33] M. Basáñez,et al. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study , 2004, The Lancet.